Home » Newsletters » BioWorld Science

BioWorld Science

March 24, 2021

View Archived Issues

FDA approves IND for JAR-914 in Duchenne muscular dystrophy

Remdesivir data in pediatric patients with COVID-19

MGTA-145 plus plerixafor effectively mobilizes stem cells for transplant in phase I study

Phase II trial underway in Mali for CIS-43LS to prevent P. falciparum infection

Izcargo approved in Japan for the treatment of MPS II

U.S. researchers patent GTPase KRAS mutant inhibitors

Ofatumumab approved in Japan for multiple sclerosis

Janssen's Darzquro approved for multiple myeloma in Japan

Breyanzi CAR-T therapy receives lymphoma approvals in Japan

ChemWerth presents new JAK1 inhibitors

Bristol Myers Squibb divulges DGKA and/or DGKZ inhibitors

Idorsia Pharmaceuticals synthesizes LGALS inhibitors

Biotest presents FVIII-based recombinant proteins for hemophilia A

First trial evaluating KCNQ2/3 positive modulator ezogabine in depression and anhedonia

Japanese approval of Lenvima for unresectable thymic carcinoma

Japanese MHLW approves Remitoro for relapsed or refractory PTCL and CTCL

Basilea reports further interim data from phase II study of derazantinib in bile duct cancer

LINC-4 phase III data presented for osilodrostat in patients with Cushing's disease

GAUSS identifies subsets, improves UK Biobank interpretation

Kinase links innate immunity to MDS

Phase II data for xanomeline/trospium as therapy for patients with schizophrenia

Clover initiates phase II/III study of adjuvanted S-Trimer COVID-19 vaccine candidate

LIBERTY randomized withdrawal study of relugolix combination therapy meets primary endpoint

ProQR plans phase II/III studies with QR-421a in Usher syndrome based on phase I/II trial analysis

FDA clears IND for phase I/II trial of EO-2463 for indolent NHL

CVnCoV protects against SARS-CoV-2 B.1.351 variant in preclinical challenge study

Ostabaro approved in Japan for osteoporosis in patients at high risk of fractures

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...